Jianjun Xiao

482 citations
16 papers · 222 indexed · h-index 9
Topics
Advanced Breast Cancer Therapies (4 papers)HER2/EGFR in Cancer Research (4 papers)Cancer Treatment and Pharmacology (3 papers)

In The Last Decade

Jianjun Xiao

15 papers receiving 221 citations

Peers

Jianjun Xiao
Comparison fields: 5 of 47
  • Oncology 115
  • Molecular Biology 89
  • Cancer Research 75
  • Pulmonary and Respiratory Medicine 72
  • Immunology 30
Replace Patrick Wenzel with:
Patrick Wenzel Germany
Diana Nariţa Romania
Simona Frezzini Italy
Nobuhiko Nishijima Japan
Huiyun Cai China
Guanhua Wu China
Gaofeng Li China
Mark Laible Germany
Jiangzheng Zeng China
Nathalie Rioux-Leclerc France
Jianjun Xiao relative to Patrick Wenzel Germany Patrick Wenzel's profile →
Citations per field
00.5×1.5×2.2×
Patrick Wenzel · 1×
Citations per year

Countries citing papers authored by Jianjun Xiao

Since Specialization
Citations

This map shows the geographic impact of Jianjun Xiao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianjun Xiao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianjun Xiao more than expected).

Fields of papers citing papers by Jianjun Xiao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jianjun Xiao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianjun Xiao. The network helps show where Jianjun Xiao may publish in the future.

Co-authorship network of co-authors of Jianjun Xiao

This figure shows the co-authorship network connecting the top 25 collaborators of Jianjun Xiao. A scholar is included among the top collaborators of Jianjun Xiao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jianjun Xiao. Jianjun Xiao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
#WorkIndexed citations
1 2
2 1
3 2
4 9
5 8
6 31
7 6
8 0
9 44
10 4
11 36
12 46
13 15
14 8
15
[Expression of HER-2/neu oncogene in hepatocellular carcinoma and the clinical implications].
9
16
Management of Tumour Lysis Syndrome in Non-Hodgkin Lymphoma
1

About Jianjun Xiao

Jianjun Xiao is a scholar working on Oncology, Cancer Research and Hepatology, having authored 16 papers that have together received 222 indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (4 papers), HER2/EGFR in Cancer Research (4 papers) and Cancer Treatment and Pharmacology (3 papers). The work is most often cited by research in Cancer Research (75 citations), Oncology (115 citations) and Pulmonary and Respiratory Medicine (72 citations). Jianjun Xiao has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Junkai Zhang, Wenjing Dong, Mancheng Gong, Yida Zhang, Li Li, Dongying Liu, Jiewen Peng, Zhongjun Xia, Antonio Gualberto and Elizabeth Claire Dees. Their work appears in journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026